Education
About Us
Working with TipRanks
Follow Us
Mckesson Corp. (MCK)
NYSE:MCK
MCK Stock Chart & Stats
$866.03
$1.72(0.29%)
At close: 4:00 PM EST
$866.03
$1.72(0.29%)
Day’s Range― - ―
52-Week Range$558.13 - $869.74
Previous CloseN/A
Volume137.88K
Average Volume (3M)678.17K
Market Cap
$105.22B
Enterprise Value$102.95B
Total Cash (Recent Filing)$4.11B
Total Debt (Recent Filing)$9.79B
Price to Earnings (P/E)26.5
Beta0.27
Next Earnings
Feb 04, 2026EPS Estimate
9.2Last Dividend Ex-Date
Sep 02, 2025Dividend Yield0.36%
Share Statistics
EPS (TTM)9.86
Shares Outstanding123,426,650
10 Day Avg. Volume781,740
30 Day Avg. Volume678,167
Financial Highlights & Ratios
PEG Ratio1.77
Price to Book (P/B)-41.34
Price to Sales (P/S)0.24
P/FCF Ratio16.41
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue0.27
Enterprise Value/Gross Profit7.94
Enterprise Value/Ebitda17.50
Forecast
1Y Price Target
$928.73Price Target Upside7.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)38.64
Revenue Forecast (FY)$408.23B
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceMcKesson Corporation reported strong quarterly results, driven by impressive performance in North America Pharma and Oncology & Multispecialty segments.
Guidance And ForecastsThe company raised its full-year adjusted earnings per share guidance, indicating management's confidence in future performance.
Oncology Business GrowthPRISM and FCS are expected to contribute 30-34% of Oncology/Multispecialty AOI growth in FY26, implying approximately 19% organic growth, ahead of long-term plan 13-16%.
Bears Say
Service Provision ExpectationsManagement does not expect the remaining company to benefit from providing services to Med Surg after its expected spinout.
Spin-off ChallengesThe potential spin-off of MedSurg faces challenges due to competition and industry trends, which are seen as somewhat challenging.
Stock Valuation ConcernsMedSurg peers trade at a discount to MCK’s current valuation, which is the biggest headwind to further multiple expansion for MCK.
McKesson News
MCK FAQ
What was Mckesson Corp.’s price range in the past 12 months?
Mckesson Corp. lowest stock price was $558.13 and its highest was $869.74 in the past 12 months.
What is Mckesson Corp.’s market cap?
Mckesson Corp.’s market cap is $105.22B.
When is Mckesson Corp.’s upcoming earnings report date?
Mckesson Corp.’s upcoming earnings report date is Feb 04, 2026 which is in 73 days.
How were Mckesson Corp.’s earnings last quarter?
Mckesson Corp. released its earnings results on Nov 05, 2025. The company reported $9.86 earnings per share for the quarter, beating the consensus estimate of $9.03 by $0.83.
Is Mckesson Corp. overvalued?
According to Wall Street analysts Mckesson Corp.’s price is currently Undervalued.
Does Mckesson Corp. pay dividends?
Mckesson Corp. pays a Quarterly dividend of $0.82 which represents an annual dividend yield of 0.36%. See more information on Mckesson Corp. dividends here
What is Mckesson Corp.’s EPS estimate?
Mckesson Corp.’s EPS estimate is 9.2.
How many shares outstanding does Mckesson Corp. have?
Mckesson Corp. has 123,426,650 shares outstanding.
What happened to Mckesson Corp.’s price movement after its last earnings report?
Mckesson Corp. reported an EPS of $9.86 in its last earnings report, beating expectations of $9.03. Following the earnings report the stock price went up 1.7%.
Which hedge fund is a major shareholder of Mckesson Corp.?
Currently, no hedge funds are holding shares in MCK
McKesson Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$928.73 (7.24% Upside)
$928.73 (7.24% Upside)
Blogger Sentiment
Bullish
MCK Sentiment 88%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 4.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.20%
Trailing 12-Months
Company Description
Mckesson Corp.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
MCK Company Deck
MCK Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
McKesson reported strong financial performance with significant growth in revenue and earnings, driven by robust performance in oncology and multispecialty segments and prescription technology solutions. The company raised its earnings guidance, reflecting confidence in continued growth. However, challenges in the Medical-Surgical Solutions segment present some concerns. Overall, the strengths significantly outweigh the challenges.View all MCK earnings summariesMCK Revenue Breakdown
91.27% U.S. Pharmaceutical
4.10% International
3.17% Medical-Surgical Solutions
1.45% Prescription Technology Solutions
MCK Stock 12 Month Forecast
Average Price Target
$928.73
▲(7.24% Upside)
Technical Analysis
Cencora
―
Cardinal Health
―
Henry Schein
―
Owens & Minor
―
Prestige Consumer Healthcare
―
Ownership Overview
0.03% Insiders
24.76% Mutual Funds
7.34% Other Institutional Investors
45.94% Public Companies and Individual Investors